Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective for intermediate-grade or immunoblastic non-Hodgkin's lymphoma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have intermediate-grade or immunoblastic non-Hodgkin's lymphoma.

Conditions

• Lymphoma

Interventions

BIOLOGICAL

bleomycin sulfate

DRUG

CHOP regimen

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

idarubicin

DRUG

ifosfamide

DRUG

mesna

DRUG

methylprednisolone

DRUG

mitoxantrone hydrochloride

DRUG

prednisone

DRUG

vincristine sulfate

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Fernando Cabanillas, MD · M.D. Anderson Cancer Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

15 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1994-05-25

Primary Completion

2007-02-05

Completion

2007-02-05

Countries

• United States
• Brazil
• Chile

Study Locations